Paul Jantzen, Product Manager for IncuCyte at Sartorius talks about the benefits of real-time live-cell analysis and image processing workflows. We also discussed how live-cell analysis is enabling the use of neuronal cell models to study cell health, morphology, function and cell dynamics.
Dr. Paul Wotton, Chief Executive Officer, Obsidian Therapeutics talks about the evolution of cancer therapy and new advancements in the space including precision medicine. Our discussion included Obsidian's cytoDRiVE™ platform that provides a technology, in which the level and timing of protein activity are fully controlled in a dose-dependent manner by an FDA-approved small molecule.
Shareen Doak and Dr. Wolfgang Moritz talk about the use of 3D cell-based human liver microtissue models to predict the adverse effects of chronic exposure to nanomaterial . We also discussed the use of liver microtissue models for drug discovery and development.
In this podcast, we interviewed Dr. J.J. Luo, Executive Director and Dr. Lily Yin, Head of Biologics Conjugation Development, at WuXi Biologics about the state of the ADC marketplace and the challenges in developing antibody drug conjugates. We then dove into reasons behind why they built a dedicated manufacturing facility for ADCs and other bioconjugates and how a single-source development platform … Continue reading Antibody Drug Conjugate (ADC) Development and Manufacturing Challenges and...
We interviewed Dr. Manny Litchman, President and CEO, Mustang Bio and Dr. Knut Niss, Chief Technology Officer, Mustang Bio about the exciting study results for their gene therapy candidate to treat XSCID, why this disease is a good fit for gene therapy and next steps.
We interviewed Dr. Andreas Castan, Principal Scientist at GE Healthcare Life Sciences about the best methods for optimizing perfusion processes. This included a discussion of tools for media optimization and innovative cell separation techniques.
In this podcast and accompanying article, we interviewed Dr. Kimberly Wicklund, Head of Product Management for the IncuCyte at Sartorius about how live cell analysis is meeting the needs of advanced cell models and how the launch of the new IncuCyte SX1 is providing scientists more options when it comes to using live cell analysis in their workflows.
In this podcast, we interviewed Dr. Alex Chatel, Product Manager, Viral Applications, Univercells about the biggest challenges facing vaccine manufacturing today, why it is so difficult to manufacture and deliver vaccines to the developing world and how a novel technology with the support of the Gates Foundation is poised to address these challenges. I began … Continue reading Innovative vaccine manufacturing enables the delivery of vaccines to the developing world →
We interviewed Dr. Aline Zimmer, Head of R&D, Advanced Cell Culture Technologies at Merck about the importance of optimizing fed batch cell culture for successful biomanufacturing. Aline discussed how her team has developing new tools and methods for optimizing fed batch culture and the impact this has had on productivity and product quality.
Cell Culture Hero, Dr. Hillary Stires discusses her work researching better treatment options for triple positive breast cancer patients. She explains how the use of cell culture modeling helps drive her research. She also talks about her experience as a cell culture hero and her passion for the scicomm movement on social media platforms.
In this podcast, we interviewed Dr. Rick Morris, Senior Vice President, R&D, Biotech, Pall Life Sciences, about integrating bioprocessing steps to improve efficiency, reduce cost and address current challenges in the industry. Specifically, we looked at how upstream and downstream can be more integrated and how to increase integration in existing facilities. View show notes … Continue reading Integrating bioprocessing steps to improve efficiency and reduce cost →
In this podcast, we interviewed Mr. Dave Eansor President of the Protein Sciences Segment at Bio-Techne and Dr. Sean Kevlahan, Senior Director of Cell and Gene Therapy at Bio-Techne about new technologies that can be implemented to expedite cell and gene therapy workflows and facilitate the path from bench to clinic. View show notes at … Continue reading Expediting cell and gene therapy workflows →
In this podcast, we interviewed Dr. Andreas Castan, Principal Scientist at GE Healthcare Life Sciences about the most efficient ways to optimize fed-batch cell culture production for CHO-based antibodies. This included a discussion of media vs. feed strategies, incorporating critical quality attributes, evaluating the impact of optimizing on downstream processing and more. View show notes at cellculturedish.com/efficient-fed-batch-cell-culture-optimization/
In this podcast, we interviewed Dr. Mats Lundgren, Ph.D. Customer Applications Director, Life Sciences, GE Healthcare, Sweden about developing platform processes for viral vector manufacturing and Mats describes a recently developed platform process for adenovirus production. View show notes at cellculturedish.com/viral-vector-manufacturing-for-gene-therapy-developing-a-platform-process/
This podcast is a recording from the panel discussion that I moderated at this year’s Cell and Gene Therapy Bioprocessing and Commercialization Conference. The discussion covers the latest in gene therapy manufacturing strategies, analytical analysis, cost of goods and key regulatory considerations. View show notes at cellculturedish.com/key-considerations-gene-therapy-manufacturing-commercialization-panel-discussion/
In this podcast, we conducted a panel discussion on key considerations for moving cell therapies from lab to commercial manufacturing, including the benefits of manufacturing in a closed system. We also discussed what were some of the key hurdles and possible solutions associated with transitioning to clinical and commercial cell therapy manufacturing. View show notes … Continue reading Closed System Cell Therapy Manufacturing – Moving from the lab to clinical and commercial production →
In this podcast, we interviewed Avril Vermunt, bioprocess hardware specialist at GE healthcare about transferring a process from a non-GMP to a GMP environment, particularly how resource-intensive it is for process development and manufacturing groups. Avril has several years of experience working in the technology transfer group at a large pharmaceutical company. We discussed with … Continue reading Start With The End In Mind. How to facilitate transfer from non-GMP to GMP →
In this podcast, we interviewed Dr. Yuyi Shen about the benefits of modeling disruptive technologies to improve downstream bioprocessing and evaluating the financial impact of implementing these technologies. View show notes at downstreamcolumn.com/podcast/modeling-downstream-disruptive-technologies-to-improve-downstream-bioprocessing/